Candesartan Effect in Second Stage Arterial Hypertension

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Candesartan; Candesartan cilexetil; Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Stage II essential hypertension (SBP≥ 160 or DBP≥100 mmHg), untreated, or treated with a maximum of 2 class of antihypertensive drugs

Exclusion Criteria:

• Current serum-creatinine >3 mg/dL, Current serum-potassium >5.5 mmol/L, 16.

• Pregnant or lactating women or women of childbearing potential who were not protected from pregnancy